Be there. The patients need to be there. Feedback about that particular disease would have been so helpful had the decision-makers known how different these medications were.
The study is available, should the committee want it. It's in the PPI class, which is for proton pump inhibitors for gastroesophageal reflux disease, which is a seemingly easy disease to manage, and yet 25% of the people failed when they had to go onto the designated products.
Had the decision-makers known about this kind of variance.... These medications all work. They all work, but not for everyone.